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Abstract
Background: Norovirus GII.4 is the predominant genotype circulating worldwide over the last decade causing 80% of all
norovirus outbreaks with new GII.4 variants reported in parallel with periodic epidemic waves of norovirus outbreaks. The
circulating new GII.4 variants and the epidemiology of norovirus outbreaks in Alberta, Canada have not been described. Our
hypothesis is that the periodic epidemic norovirus outbreak activity in Alberta was driven by new GII.4 variants evolving by
genetic drift.
Methodology/Principal Findings: The Alberta Provincial Public Health Laboratory performed norovirus testing using RT-
PCR for suspected norovirus outbreaks in the province and the northern Territories between 2000 and 2008. At least one
norovirus strain from 707 out of 1,057 (66.9%) confirmed norovirus outbreaks were successfully sequenced. Phylogenetic
analysis was performed using BioNumerics and 617 (91.1%) outbreaks were characterized as caused by GII.4 with 598
assigned as novel variants including: GII.4-1996, GII.4-2002, GII.4-2004, GII.4-2006a, GII.4-2006b, GII.4-2008a and GII.4-2008b.
Defining July to June of the following year as the yearly observation period, there was clear biannual pattern of low and
high outbreak activity in Alberta. Within this biannual pattern, high outbreak activity followed the emergence of novel GII.4
variants. The two variants that emerged in 2006 had wider geographic distribution and resulted in higher outbreak activity
compared to other variants. The outbreak settings were analyzed. Community-based group residence was the most
common for both GII.4 variants and non-GII.4 variants. GII.4 variants were more commonly associated with outbreaks in
acute care hospitals while outbreaks associated non-GII.4 variants were more commonly seen in school and community
social events settings (p,0.01).
Conclusions/Significance: The emergence of new norovirus GII.4 variants resulted in an increased norovirus outbreak
activity in the following season in a unique biannual pattern in Alberta over an eight year period. The association between
antigenic drift of GII.4 strains and epidemic norovirus outbreak activity could be due to changes in host immunity, viral
receptor binding efficiency or virulence factors in the new variants. Early detection of novel GII.4 variants provides vital
information that could be used to forecast the norovirus outbreak burden, enhance public health preparedness and allocate
appropriate resources for outbreak management.
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Introduction
Norovirus (NoV) is recognized as the most common cause of
gastroenteritis outbreaks worldwide. NoV outbreaks occur fre-
quently in nursing homes, health care institutions, cruise ships and
have also been reported in schools and prisons [1–3], causing
considerable morbidity and mortality in these settings [4].
Noroviruses are extremely contagious with the minimal infectious
dose as low as 10 viral particles [5] while the amount of virus shed
by infected individuals is high (over 10
8 RNA copies per gram of
stool) [6–8]. Transmissibility is enhanced by the stability of NoV in
the environment and its resistance to disinfection [9]. Norovirus
can be transmitted by contaminated food and water, person to
person spread, and exposure to aerosols from vomitus [10–12].
Norovirus outbreak is therefore a challenge to manage and control
and has considerable health and economic impact.
Norovirus is a genetically diverse group of virus belonging to the
family Caliciviridae. There are currently five genogroups (GI–GV).
GIII has only been found in cattle [13,14] and GV only in mice
[15,16]. GI (8 genotypes) and GII (17 genotypes) contain most of
the strains infecting humans [16]. The NoV GII.4 genotype has
been the predominant genotype circulating in the US, Europe and
Oceania over the past decade and has caused up to 80% of all
NoV outbreaks, particularly those occurring in healthcare settings
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have evolved over the last 20 years and in parallel, NoV outbreaks
of epidemic proportion have been observed [21]. The pandemic
spread of new GII.4 variants was first recognized in the mid-1990s
[22]. In 1995–1996, strain US95/96 was responsible for about
55% of NoV outbreaks in the US and 85% in the Netherlands
[23]. Between 2000 and 2004, US95/96 was replaced by two new
GII.4 variants, the Farmington Hill strain [3], which was
associated with 80% of the US NoV outbreaks [1]. During the
same period in Europe, the new GII.4 variant caused outbreaks
during the winter, spring and summer [24–26]. In 2004, the
Hunter GII.4 variant was detected in Australia, Europe, and Asia
[26–28]. This strain was then replaced by two co-circulating GII.4
variants in the US, Europe, and Asia in early 2006 [4]. Between
2007 and 2008, two new GII.4 variants emerged and were
reported by the food-borne viruses in Europe (FBVE) Network
(Joukje J., personal communication). All NoV GII.4 variants are
genetically linked and have been classified internationally as novel
GII.4 variants 1996, 2002, 2004, 2006a, 2006b and 2008
respectively.
The circulation of NoV GII.4 variants in Alberta and northern
Territories in Canada and the epidemiology of gastroenteritis
outbreaks has not been described. We examined nine years of
gastrointestinal outbreak data (2000–2008) and studied the
emergence and circulation of new GII.4 variants and their
association with NoV gastroenteritis outbreak activity.
Methods
Ethics Statement
Health ethics was not requested as this study was part of routine
laboratory-based outbreak investigation and identifiable informa-
tion of the outbreaks was not included in the analysis. Patient
consents were not required as they were tested as per routine
outbreak laboratory investigations and patient demographic
information was not included in the analysis.
Laboratory investigation of gastroenteritis outbreaks
All suspected gastrointestinal outbreaks in the province of
Alberta, Canada are identified and investigated through the
provincial public health system using standardized protocols and
tracking systems established since 1999. Between March 2004 and
March 2009, the province was divided into nine health regions,
including: two metropolitan regions each with a population .1
million and seven non-metro regions with populations ranging
from 82.8 K to 183.5 K. The Alberta Provincial Public Health
Laboratory (ProvLab) performed laboratory investigations on stool
samples from all gastroenteritis outbreaks in Central and Northern
Alberta between 1999 and February 2002 and for the whole
province from March of 2002 onward. ProvLab also provided
laboratory investigation support for gastroenteritis outbreaks in the
northern territories in Canada (the Northwest Territories, Yukon
and Nunavut) during this period. The settings of the outbreaks
were recorded in ProvLab database and could be classified as one
of the followings: group residence, senior residence, long term
care, hospital long term care, hospital acute care, daycare, school,
community gathering, conference, food establishment, cruise/
hotel, private households, community shelter/service, region-
based community and others.
If NoV was the suspected etiological agent for a gastroenteritis
outbreak, stool specimens were processed for both standard
bacterial culture and nucleic acid detection of NoV using
conventional reverse transcript PCR between 1999 and March
2004 [29] and a multiplex real time RT-PCR (Mrt RT-PCR)
assay since April 2004 [30]. At least one NoV positive specimen
from each outbreak occurring between July 2000 and June 2008
was selected for genotyping by DNA sequencing.
RT-PCR assay and Sequencing for Norovirus
The Mrt RT-PCR assay used for NoV detection in the stool
specimens from gastroenteritis outbreaks and the methods for
nucleotide sequencing to characterize NoV genotype and variants
were previously described by Pang et al [30,31]. Briefly, total
nucleic acid from 200 ml of 10% stool suspension was extracted
and eluted into 100 ml using Magazorb
TM RNA extraction kit
(CORTEX Biochem, CA, USA) by automatic extraction or
easyMAG (bioMe ´rieux) according to the manufacturer’s instruc-
tions. cDNA was synthesized using random hexamer and Super-
Script
TM II RNase H
-Reverse Transcriptase kit (Invitrogen, CA,
USA). Five micro liters of cDNA was used for detection of NoV
and the remaining cDNA sample was stored at minus 20uC for
later characterization of NoV. cDNA samples tested positive for
NoV was used for amplification with primers from region E of the
capsid gene for GII and from region D for GI. If amplification
failed with the region E primers for GII, then amplification was
performed using the primers from region D for GII. The
amplicons (GII region E=320 bp, GII region D=253, and GI
region D=177 bp) were purified using Qiagen purification kit
(Qiagen, Chatsworth, CA, USA). Sequencing was performed using
the BigDyeH Terminator v3.1 Cycle Sequencing Kit (Applied
Biosystems) in the ABI PRISMH 3100-Avant Genetic Analyzer.
Sequencing analysis utilized the Data Collection Software v2.0
(Applied Biosystems).
Phylogenetic Analysis
Primary sequence data was assembled and the consensus
sequence from each amplicon was generated using the sequence
software BioNumerics 5.1. The sequence data was blasted
against the database (GenBank, NCBI) to confirm the NoV
assignment before performing the phylogenetic analysis. Pairwise
alignments and multiple alignments of DNA sequences were
performed with the default parameters. A minimum spanning
tree was constructed based on 320 nucleotides in the E region of
the capsid gene using the neighbor-joining algorithm with
BioNumerics software (version 5.1; Applied Maths Sint-Mar-
tens-Latem, Belgium).
Norovirus genogroup, genotypes and the GII.4 variants were
assigned using the reference GenBank access numbers and
nomenclature described by Zheng et al in 2006 [16], the FBVE
network and CaliciNet, US (Dr. M Koopmans and Dr. J Vijin,
personal communication) as shown in Table 1.
Definition of the observation period, setting and
epidemic year for NoV outbreaks
The annual observation period for NoV gastroenteritis
outbreaks was defined as the period beginning in July and ending
in June of the following year to improve the capture of the winter
seasonality of NoV outbreaks. Norovirus outbreaks always peaked
between the months of November to March. This seasonal
assignment allowed better analysis of the annual fluctuations of
NoV outbreak burden and its relationship to strain variation and
evolution. For this study, an epidemic year was defined as when
the number of NoV outbreaks during the 12-month period was
$2 times higher than the numbers of outbreaks in the period
before and after the observation period. The observation periods
with a relatively low number of NoV outbreaks were designated as
quiescent years.
NoV GII.4 Variant Outbreaks
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residence, senior residence and long term care were grouped
together as community-based group residence. Outbreaks in
community gatherings, conference and food establishments were
considered as similar setting with sharing of food and beverages
and were classified as community social events.
Data Analysis
The difference in the number of NoV outbreaks by observation
periods and the association of new variant strains and epidemic
year was analyzed using binary logistic regression. Chi Square
Test or Fisher Exact test as appropriate with Bonferroni correction
was used to analyze the difference in NoV outbreaks for GII.4
variants and non-GII.4 variants in the following outbreak settings:
community-based group residence, hospital long-term care,
hospital acute care, community social events and school.
Results
Norovirus outbreaks and distribution pattern
Duringthe 8 year studyperiod(July 1, 2000–June 30, 2008), stool
samples from 1,480 gastroenteritis outbreaks were tested for NoV.
Norovirus was identified as the causative agent in 1,057 outbreaks
(71.4%). Confirmed NoV outbreaks demonstrated a clear alternat-
ing pattern of epidemic and quiescent years. Observed NoV
outbreak activity per year (n=number of NoV outbreaks, %
outbreaks NoV positive) was as follows during quiescent years:
2001–02 (n=15, 57.7%), 2003–04 (n=68, 64.2%), 2005–06
Table 1. Norovirus GII reference genotypes used in this study.
*GII genotypes Name of strain Accession number in GeneBank
GII.1 Hawaii/71/US U07611
GII.2 Ina/02/JP AB195225
GII.2 Snowmount/76/US U75682
GII.3 Oberhausen455/01/DE AF539440
GII.3 Toronro24/91/CA U02030
GII.4 Lordsdale/93/K X86557
GII.4 Bristol virus/94/UK X76716
GII.5 Hillingdon/94/U AJ277607
GII.5 Hokkaido133/03/J AB212306
GII.6 Seacroft/90/UK AJ277620
GII.7 Leeds/90/UK AJ277608
GII.8 Amsterdam/98/NL AF195848
GII.9 Virginia207/97/US AY038599
GII.10 Erfurt-546/00/DE AF427118
GII.11 Sw918/97/JP AB074893
GII.12 Wortley/90/UK AJ277618
GII.13 Fayetteville/98/US AY113106
GII.14 M7/99/US AY130761
GII.15 J23/99/US AY130762
GII.16 Tiffin/99/US AY502010
GII.17 CS-E1/02/US AY502009
{GII.4 Variants Name of strain Accession number in GeneBank Causing epidemic NOG worldwide
1996 DenHaag015/00-NL AB303923 Before 2001
1996 Grimsby AJ004864 Before 2001
2002 Farmington Hills/02/US AY502023 2002–2003
2002 Haarlem457/2003-NL AB303933 2002–2003
2004 0317/04/NL AY883096 2004–2005
2004 Hunter 284E/04O/AU DQ078794 2004–2005
2006a Terneuzen70/06-NL EF126964 2006–2007
2006a Yerseke38/06/NL EF126963 2006–2007
2006b Nijmegen115/06/NL EF126966 2006–2007
2006b Minerva/06/UA EU078417 2006–2007
2008a OC07138/Jap AB434770 Ongoing surveillance
2008b Apeldoorn317/07/NL AB445395 Ongoing surveillance
*Zheng et al. Virology, 2006.
{Personal communication from the Food-borne Viruses in Europe (FBVE) and Centers for Disease Control and Prevention (CDC) in US Network.
doi:10.1371/journal.pone.0011599.t001
NoV GII.4 Variant Outbreaks
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2000–01 (n=58, 78.4%), 2002–03 (n=191, 78.0%), 2004–05
(n=205, 81.7%) and 2006–07 (n=313, 72.6%), respectively
(Table 2 and Figure 1). The proportion and number of
gastroenteritis outbreaks caused by NoV was significantly higher
during epidemic as compared to quiescent years (p,0.0001, binary
logistic regression). This observation is independent of the variation
in the number of NoV outbreaks in all eight observation periods.
The number of NoV outbreaks observed increased over time in
both epidemic as well as quiescent years during the study period.
Table 2. Norovirus genogroup and genotypes in outbreaks during July 2000 to June 2008.
Observation Period
Jul00 to
Jun01
Jul01 to
Jun02
Jul02 to
Jun03
Jul03 to
Jun04
Jul04 to
Jun05
Jul05 to
Jun06
Jul06 to
Jun07
Jul07 to
Jun08 Total
Number of norovirus
outbreaks
58 15 191 68 205 98 313 109 1,057
Sequence (%) 21 (36.2) 3 (20.0) 77 (40.3) 29 (42.6) 158 (77.1) 56 (57.1) 268 (85.6) 95 (87.2) 707 (66.9)
G I t o t a l 0 021 6 01923 0
G II total 21 3 75 13 158 55 259 93 677
GII.1 1 1 2
GII.2 10 1 11
G I I . 3 2 14173292 9
GII.4 18 2 71 10 148 41 252 75 617
GII.5 16 7
G I I . 6 211 37
GII.9 33
GII.13 11
doi:10.1371/journal.pone.0011599.t002
Figure 1. Number of norovirus outbreaks by observation periods from July 2000 to June 2008.
doi:10.1371/journal.pone.0011599.g001
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At least one NoV was successfully sequenced from 707 of the
1,057 confirmed NoV positive outbreaks (66.9%). The median
sequencing rate was 57.1% (range 20.0–87.2%) for all observation
periods. Analysis of the outbreaks with sequence data revealed 30
NoV genogroup (GI) outbreaks that occurred primarily in the 03–
04 quiescent year (16/30, 53%) and the 06–07 epidemic year (9/
30, 30%). Most of the NoV outbreaks were caused by NoV
genogroup (GII) strains (n=677). Genogroup II predominated in
each observation period except for the period July 2003 to
June2004. Among 677 NoV GII outbreaks, 617 strains were
classified as GII.4 (91.1%), 29 as GII.3 (4.3%), 11 as GII.2 (1.6%),
7 each as GII.5 and GII.6 (1.0%). Norovirus GII.1, 9 and 13 were
detected in less than 1% of outbreaks and no GII.7, 8 and 10 to 15
was found. Norovirus genotypes/strains and associated gastroen-
teritis outbreaks are summarized in Table 2.
Temporal emergence of GII.4 variants and the epidemic
years
Between July 2000 and June 2008, six new GII.4 variants
emerged in Alberta (Table 3). The variant 1996 was identified in
the epidemic year 2000–01 and was the only NoV GII.4 variant
Table 3. Norovirus GII.4 variants in outbreaks during July 2000 to June 2008.
Observation Period
Jul00 to
Jun01
Jul01 to
Jun02
Jul02 to
Jun03
Jul03 to
Jun04
Jun04 to
Jul05
Jul05 to
Jun06
Jul06 to
Jun07
Jul07 to
Jun08
Number of norovirus GII
outbreaks by sequence
21 3 75 13 158 55 259 93
Number of GII.4 variants
outbreaks (%)
18 (85.7) 2 (66.7) 71 (94.7) 10 (76.9) 148 (93.7) 41 (74.5) 252 (97.3) 75 (80.6)
GII.4-1996 18 2
GII.4-2002 2 61 8 5
GII.4-2004 141 18
GII.4-2006a 296 2 5
GII.4-2006b 12 189 61
GII.4-2008a 1
GII.4-2008b 4
GII.4-other 10 2 1 4
doi:10.1371/journal.pone.0011599.t003
Figure 2. Emergence of new norovirus GII.4 variants from July 2000 to June 2008.
doi:10.1371/journal.pone.0011599.g002
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NoV outbreaks, a new GII.4 variant 2002 emerged in June of
2002 and caused a large number of NoV outbreaks in the
epidemic year 2002–03. In the following quiescent period 2003–
04, the variant 2002 continues to circulate but outbreak activity
associated with this variant remained low (only 10 outbreaks). In
the epidemic periods 2004–05 and 2006–07, the emergence of
new variants 2004 (August 2004), 2006a (March 2006) and 2006b
(April 2006) resulted in a pattern similar to that observed with
2002 variant. These new variants caused an even larger number of
NoV outbreaks, (n=141 in 2004–05 and n=251 in 2006–07)
respectively. Interestingly, while the 2006b and 2006a variants
arose concurrently in the spring, the 2006b variant caused three
times as many outbreaks as the 2006a variant: 189 and 62
outbreaks respectively. In the following quiescent period 2007–08,
variant 2006b remained dominant even though both variants
demonstrated decreased activity levels (Figure 2). The emergence
of new variants was significantly associated with epidemic years
(p,0.0001, binary logistic regression). The number of NoV
outbreaks associated with the newly emerged GII.4 variants
increased steadily in the four epidemic years between 2000 and
2007.
The 1996 variants were found in 4 of the 9 health regions in
Alberta, the 2002 variant in 7 regions, the 2004 variant in 8 regions
and an outbreak in Nunavut, the 2006a variant in 6 regions as well
as a provincial outbreak and an outbreak in Yukon, and the 2006b
variant in all 9 health regions in Alberta and an outbreak in the
Northwest Territory. Both the 2002 and 2006a variant spanned
four observation periods, with circulation observed between June
2002 and October 2004 and March 2006 to June 2008 respectively.
The 1996 variant circulated from October 2000 to January 2001
and reappeared in November of 2003.
Alignment analysis on 320 nucleotides in the E region of the
capsid gene demonstrated the genetic distances between newly
emerging variants and the previous ones. Most of the variants
seemed to have evolved from their antecedent temporal variants
with a varying number of nucleotide changes, as illustrated by
comparing variant 2004 to variant 2002. However, genetic
lineages of the variant 2006b and 2006a were completely different,
with the 2006b variant linked closely to the1996 variant and the
2006a variant to the 2004 variant. Interestingly, both strains were
associated with NoV outbreaks in the same epidemic year
(Figure 3).
Clinical settings of GII.4 variants and non-GII.4 variants
outbreaks
The three most common settings for outbreaks caused by
GII.4 variants were community-based group residence (n=427,
69.2%) followed by hospital long-term-care (n=92, 14.9%),
hospital acute care (n=44, 7.1%). The three most common
settings for non-GII.4 variant outbreaks were community-based
group residence (n=56, 62.2%), followed by schools (n=8,
8.9%) then community social events (n=7, 7.8%) (Table 4).
Outbreaks associated with GII.4 variants as compared to non-
GII.4 variant were significantly more common in the settings of
hospital acute care (p,0.01, Chi square test with Bonferroni
correction) while outbreaks associated with non GII.4 variants
were significantly more common in the settings of school and
community social events (p,0.005, Fisher Exact test with
Bonferroni correction). Most of the outbreaks in hospital acute
Figure 3 Phylogenetic tree of region E of the norovirus capsid. This figure is generated by using the neighbor-joining algorithm with
BioNumerics software (version 5.1; Applied Maths Sint-Martens-Latem, Belgium).
doi:10.1371/journal.pone.0011599.g003
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GII.2004 (n=21, 22.8%).
Discussion
By defining the annual observation period in our study in a
unique way rather than by calendar year as in other studies
[17,19,32], and access to a unique population-based dataset
spanning eight years of gastrointestinal outbreaks investigated
using standardized protocols allowed us to clearly observe a
distinct pattern of alternating epidemic and quiescent years of
NoV outbreak activity in Alberta and the northern Territories.
This pattern was temporally associated with the emergence of
distinctly different GII.4 variant strains. A persistent and temporal
genetic drift in NoV capsid sequences was also reported worldwide
[17,27,32–35]. The reason for the frequent antigenic drift of GII.4
strains resulting in critical amino acids changes (antigenic drift) in
the P2 domain of the viral capsid protein binding site [35–38] is
not understood.
Lindesmith et al. studied the molecular mechanism of GII.4
NoV evolution resulting in the persistence and emergence of
new strains [21]. The emergent variants appear to have a
transmissibility advantage and increased virulence as document-
ed by the high prevalence of NoV outbreaks caused by variant
2006b/a and the steady increase in the number of NoV
outbreaks over the 8 years of this study. It has been
hypothesized that GII.4 NoV persist by altering their ABH
histo-blood group antigens (HBGAs) carbohydrate-binding
targets over time, allowing for escape from host susceptibility
alleles that are highly penetrant.
An alternate explanation is that evolving strains drift under
immune selective pressure until mutations have accumulated to
the point where a novel genetic variant phenotype becomes
established and evade from pre-established host immunity [35]. A
similar phylodynamic pattern of epochal evolution has been
described for influenza A virus (H3N2) [39]. Short-term
protective antibodies against NoV previously described usually
waned after 6 months in the absence of re-exposure [40–42].
Some new variants persisted for a long period of time at a low
level which could be explained by ongoing mutations that
allowed partial but incomplete evasion of the host immune
response but did not result in increased virulence or circulation in
a totally immunologically naı ¨ve population that would result in
activity levels of epidemic proportion. Further studies on the
immune response to NoV within populations and the duration of
protective immunity against prevalent genetic variants are
urgently needed.
Early detection of novel GII.4 variants could be used to forecast
the NoV outbreak burden and allows enhanced surveillance and
early implementation of preventive measures in populations and
settings where outbreaks would most likely occur. We observed a
time lag of 4 to 6 months between the initial circulation of new
variants and the outbreak peak in the subsequent epidemic year.
This would be the available time frame for the development of
future vaccine if such capacity becomes available for NoV.
We demonstrated clearly that a single novel variant of NoV
GII.4 caused the majority of outbreaks in four epidemic years in
this study, similar to other reports with variable periods of
observation from different continents [17,27,32–35]. However, the
high prevalence of NoV outbreaks in the epidemic year 06–07 was
caused by two of GII.4 variants that had emerged simultaneously
(2006a and 2006b) and the total number of NoV outbreaks
observed was higher than those identified in previous epidemic
years. The global increase in NoV outbreaks in 2006 was linked to
these two new variants [19,20]. In contrast with the data from
New Zealand and Australia [20] but consistent with observations
from studies reported in the US [4] Netherlands [19] and Eastern
Spain [17], the 2006b variant caused significantly more outbreaks
than the 2006a variant during this period in Alberta. Siebenga
et al. studied the nucleic acid and protein structure of the P2
domain of NoV capsid protein in epidemic NoV variants that
emerged between 1996 and 2006 [35]. They found that the 2006a
variant resulted in 8 amino acid substitutions whereas the 2006b
variant had 25 amino acid substitutions in the capsid protein when
compared to its predecessor, the 2004 variant. The genetic lineage
of the 2006b variant was closer to the 2002 variant than to the
2004 variant in the polymerase gene region. Our results showed
that genetic lineage of the 2006b was derived from the 1996
variant, whereas the 2006a variant was closer to the 2004 variant
based on alignment in the E region of the capsid gene. The 2006b
variant appears to have emerged from an earlier strain that had
accumulated more mutations after a long period of stasis. We
hypothesize that an epochal change occurred in the 2006b variant
resulting in a significant number of amino acid substitutions
leading to a distinct phenotype with better host evasion capability
and higher transmissibility. 2006 was the first time during our
observation period that two new variants emerged during the same
year. Ongoing surveillance of the circulatory pattern of these
strains would be critical to our understanding of the dynamics of
co-circulation of NoV variants.
As observed in all NoV outbreaks worldwide [42], most of the
NoV outbreaks occurred in closed settings in Alberta such as
community-based group residence and hospital long term care
facilities. The non-GII.4 variant were found to be significantly
associated with outbreaks in in schools and community social
events as compared to GII.4 variants. The number of outbreaks
per observation in these two settings were small but consistent
during the study period (data not shown) making the observation
unlikely to be a result of temporal bias. In a previous study, we
reported a broader range of NoV genotypes in sporadic
gastroenteritis in young children as compared to outbreaks [31].
Table 4. The type of settings of outbreaks caused by GII.4
variants and non-GII.4 variants.
Outbreak
settings
Norovirus
outbreaks
from GII.4
variants
Norovirus outbreaks
from Non-GII.4
variants
Community-based
group residence
427 (69.2%) 56 (62.2%)
Hospital acute care 92 (14.9%) 2 (2.2%)
Hospital long term care 44 (7.1%) 2 (2.2%)
School 8 (1.3%) 8 (8.9%)
Community social event 22 (3.6%) 7 (7.8%)
Community shelter/service 6 (0.1%) 3 (3.3%)
Cruise/hotel 6 (0.1%) 3 (3.3%)
Daycare 4 (0.1%) 5 (5.5%)
Private household 4 (0.1%) 3 (3.3%)
Region-based community 2 (0.03%) 1 (1.1%)
Hospital (setting not defined) 1 (0.002%) 0 (0)
Other 1 (0.002%) 0 (0)
Total 617 90
doi:10.1371/journal.pone.0011599.t004
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common in outbreaks in the younger populations. The finding
might reflect differences of age-related susceptibility to different
NoV stains. The population in hospital acute care was at higher
risk for NoV outbreaks cause by novel variants and could be an
important target for molecular surveillance for new strains.
Our study supported the importance of ongoing surveillance of
circulating NoV strains at a phylogenetic level with the
observation that the emergence of new GII.4 variants is associated
with increase in the NoV outbreak burden. Such surveillance data
has the potential to enhance public health preparedness and allow
planning for more appropriate health care resource allocation.
Further studies are needed to better understand the relationship
between the host response and emergence of new variant strains
and the dynamics of strain circulation within populations both
locally and globally.
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